Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients

Area of Science:

• Rheumatology
• Cardiovascular Health
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease.
• Cardiovascular disease (CVD) risk is elevated in RA patients.
• Hydroxychloroquine (HCQ) is a common disease-modifying antirheumatic drug (DMARD).

Purpose of the Study:

• To investigate the association between HCQ use and plasma lipid and glucose levels in RA patients.
• To determine if HCQ impacts cardiovascular risk factors in RA.
• To analyze lipid profiles and glucose levels in RA patients with varying HCQ exposure.

Main Methods:

• Retrospective cohort analysis of 1261 RA patients.
• Comparison of fasting lipid profiles and plasma glucose between HCQ users and non-users.
• Multivariable models and propensity scoring used to adjust for confounders.

Main Results:

• HCQ use was significantly associated with lower total cholesterol, LDL, triglycerides, and lipid ratios (TC/HDL, LDL/HDL).
• Patients taking HCQ showed significantly higher HDL levels.
• No significant association was found between HCQ exposure and fasting plasma glucose levels.

Conclusions:

• HCQ use in RA patients is associated with favorable lipid profiles.
• HCQ does not appear to affect plasma glucose levels in this cohort.
• Further randomized trials are warranted to confirm HCQ's role in CVD prevention for RA patients.